Table 1.
Details of MS and control subjects used in this studya
| Case no. | Sex | Age (yr) | PMD (h) | Disease duration (yr) | Cause of death | Course |
|---|---|---|---|---|---|---|
| CO32 | M | 88 | 22 | — | Prostate cancer | — |
| CO36 | M | 68 | 30 | — | Fibrosing alveolitis | — |
| CO37 | M | 84 | 5 | — | Bladder cancer | — |
| CO45 | M | 77 | 22 | — | Pneumonia | — |
| MS200 | F | 43 | 20 | 19 | Urinary tract infection | SP |
| MS203 | F | 53 | 17 | 27 | Multiple sclerosis | SP |
| MS207 | F | 46 | 10 | 25 | Pneumonia | SP |
| MS230 | F | 42 | 31 | 19 | Multiple sclerosis | SP |
| MS256 | F | 53 | 21 | 24 | Pneumonia | SP |
| MS527 | M | 47 | 10 | 25 | Pneumonia | SP |
aPMD, Postmortem delay; SP, secondary progressive MS.